Evidence map›Paper›PMID 40704343›Full record

ReviewTanaffos2024

Coronavirus in Recent Years: Characteristics, Outbreaks, and Treatments.

Touba Eslaminejad, Saeedeh Shojaeepour, Seyedeh Atekeh Torabizadeh, Vida Mirzaie

Abstract readReview
In one paragraph

Review in Tanaffos, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Touba EslaminejadDepartment of Anatomy, Afzalipour School of Medicine, Kerman University of Medical Sciences, Kerman, Iran.
Saeedeh ShojaeepourDepartment of basic sciences, Faculty of Veterinary Medicine, Shahid Bahonar University of Kerman, Kerman, Iran.
Seyedeh Atekeh TorabizadehPharmaceutics Research Centre, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran.
Vida MirzaieDepartment of Anatomy, Afzalipour School of Medicine, Kerman University of Medical Sciences, Kerman, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Coronaviruses cause acute respiratory syndromes, e.g., SARS, MERS, and COVID-19, whose treatment depends on several factors, specifically the age of patients, adopted treatments, time of hospitalization, and timely diagnosis. The present study was conducted to investigate the interaction between the mentioned factors and treatment. Materials and Methods: Relevant full-text publications were indicated by searching in the five online databases MEDLINE, EMBASE, WOS, Science Direct, and Cochrane Library using MeSH terms during 2010-2024. Only original case reports (n=55) that worked on signs and treatments were selected and analysed according to age, gender, medical history, diagnostic methods, treatments, kind of respiratory syndrome, and transmission ways. Articles that met the inclusion criteria were evaluated by each of the reviewers independently, and non-agreements were solved by consulting with a fourth reviewer. Results: According to the results, the severe respiratory syndromes occurred more in the elderly than younger people and in males than females (58% and 42%, respectively). Medical history of diabetes and heart disease showed the maximum effect on the person to get involved with the severe respiratory syndrome. Clinical methods were used more for the diagnosis of the diseases because of easy access and less time consumption. Combination therapy was better than single therapy. The most common route of transmission was human to human and nosocomial. Conclusion: It can be concluded that these types of fatal respiratory illnesses can be controlled if the health care workers become familiar with the type of illness and apply the early and effective treatments.

Indexed as

Acute Respiratory SyndromeCoronavirusesCOVID-19MERSSARS

Identifiers

PMID40704343
PMCPMC12281347

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.